Cannabis Bioscience International Holdings, Inc.

CBIH OTC SEC CIK 1411057
Follow Cannabis Bioscience International Weekly email: filings, results, news

Financials

Reported figures only · latest: Q3 2026 USD · US GAAP
Revenue, last quarter $11.2K −25% vs same quarter last year
Net income −$103.9K +42.7% vs same quarter last year
EPS, diluted $0.00
Operating cash flow −$14.6K +82.4% vs same quarter last year
Revenue by quarter
$75.9K
$178.9K
$74.2K
$14.9K
$35K
$24.2K
$53.3K
$11.2K
Q4 24 Q1 25 Q2 25 Q3 25 Q4 25 Q1 26 Q2 26 Q3 26

Source: SEC XBRL filings · latest filing

The long view

Fiscal years as reported · SEC XBRL filings, US GAAP
Revenue and net income6 fiscal years
  • Revenue
  • Net income
−$1.5M−$1M−$500K$0$500KFY10FY11FY22FY23FY24FY25
Show the numbers
YearRevenueNet income
FY25$303K−$548.8K
FY24$248.8K−$651.3K
FY23$316.8K−$1M
FY22--
FY11--
FY10--
MarginsShare of revenue
  • Gross margin
  • Operating margin
  • Net margin
−400%−200%0%200%FY10FY11FY22FY23FY24FY25
Show the numbers
YearGross marginOperating marginNet margin
FY2586.8%−139.1%−181.1%
FY2481.7%−195.4%−261.8%
FY2370.5%−310.4%−325.9%
FY22---
FY11---
FY10---
Net margin vs the sectorMedian of Healthcare companies filing with the SEC
  • Cannabis Bioscience International
  • Healthcare median
−400%−300%−200%−100%0%FY10FY11FY22FY23FY24FY25
Show the numbers
YearCannabis Bioscience InternationalHealthcare median
FY25−181.1%−40.6%
FY24−261.8%−60.7%
FY23−325.9%−97.1%
FY22-−128.5%
FY11-−76.3%
FY10--

News

No stories filed under Cannabis Bioscience International yet - coverage appears here as the news feed clusters it.